abstract: INTRODUCTION: The objective of this study was to assess tracheal reactivity after the deployment of different self-expandable metal stents (SEMS). MATERIAL AND METHODS: Forty female @entity0 were divided into four groups. Three groups received three different SEMS: steel (ST), @entity3 ( @entity5 ), or @entity3 drug-eluting stent (DES); the fourth group was the control group (no stent). Stents were deployed percutaneously under fluoroscopic guidance. Animals were assessed by multi-slice, computed tomography (CT) scans, and tracheas were collected for anatomical pathology (AP) study. Data from CT and AP were statistically analyzed and correlated. RESULTS: The DES group had the longest @entity2 (20.51  14.08mm vs. 5.84  12.43 and 6.57  6.54mm in @entity5 and ST, respectively, day 30; P<.05), and higher @entity1 formation on CT (50% of cases). The @entity5 group showed the lowest grade of @entity2 (2.86  6.91% vs. 11.28  13.98 and 15.54  25.95% in DES and ST, respectively; P<.05). The AP study revealed that the ST group developed intense proliferative reactivity compared to the other groups. In the DES group, a destructive response was observed in 70% of the animals, while the @entity5 was the least reactive stent. CT was more effective in detecting wall thickening (positive correlation of 68.9%; P<.001) than @entity1 (not significant). CONCLUSIONS: The ST group developed @entity1 and significant @entity2 . @entity5 was the least reactive stent, while DES caused significant lesions that may be related to drug dosage. This type of DES stent is therefore not recommended for the treatment of @entity4 .

title: Tracheal Self-Expandable Metallic Stents: A Comparative Study of Three Different Stents in a XXXX Model.

answer: @entity0


abstract: INTRODUCTION: Failure To Rescue was first defined in @entity0 who died due to a complication following (open) cholecystectomy but research into the relevant factors has been scarce. This study was designed to determine a chronological sequence of deficiencies in care. METHODS: Adult @entity0 who died under the care of a surgeon following cholecystectomy in Queensland were identified from the Australian and New Zealand Audit of Surgical Mortality (ANZASM) database. RESULTS: Not unexpectedly, this is a high-risk @entity0 population: median age of the 48 @entity0 was 74.5 years and the median number of comorbidities and American Society of Anesthesiologists class was 4. @entity1 occurred on postoperative day 6. Most @entity1 occurred at the end of the week. Over 80% of @entity1 followed emergency cholecystectomy. In almost half the @entity0 , there were no deficiencies in care. Most common deficiency was during postoperative management (i.e. Failure To Rescue), however, significant @entity2 prior to surgical admission; choice and timing of intervention as well as intraoperative decision-making. CONCLUSION: Surgeons who perform cholecystectomy need to be aware of the levels at which deficiencies arise given that many may be preventable.

title: XXXX in care following cholecystectomy.

answer: @entity2


abstract: UNASSIGNED: BACKGROUND The present study aimed to assess the role of @entity3 polymorphism in drug-resistance in @entity1 by a meta-analysis. MATERIAL AND METHODS Databases were obtained from the Cochrane Library, MEDLINE, EMBASE, PubMed, Science Direct database, CNKI, and Wanfang up to October 2014. All the case-control association studies evaluating the role of @entity2 @entity3 in pharmacoresistance to anti- @entity1 drug (AED) were identified. RevMan 5.0 software was utilized to perform quantitative analyses in an allele model (C vs. T) and a genotype model (CC vs. CT+TT). RESULTS From the 189 potential studies, we included 28 articles for the meta-analysis, including 30 independent case-control studies involving 4124 drug-resistant @entity1 @entity0 and 4480 @entity1 @entity0 for whom drug treatment was effective. We excluded 164 studies because of duplication, lack of genotype data, and non-clinical research. We found that @entity3 polymorphism was not significantly associated with drug resistance in @entity1 , either in allele model (C vs. T: OR=1.07; 95%CI: 0.95-1.19) or in genotype model (CC vs. CT+TT: OR=1.05; 95%CI: 0.89-1.24, P=0.55). Subgroup analyses suggested that in Caucasian populations there are significant differences between resistance group (NR) and control group (R) in both allele model (C vs. T: OR=1.09; 95%CI: 1.00-1.18, P=0.05) and genotype model (CC vs. CT+TT: OR=1.20; 95%CI: 1.04-1.40, P=0.01). However, we did not find this association in Asian populations. CONCLUSIONS We conclude that the @entity2 @entity3 polymorphism may be a genetic marker for drug resistance in @entity1 in Caucasian populations.

title: XXXX Gene @entity3 Polymorphism and Drug Resistance in Epilepsy: Evidence Based on 8604 Subjects.

answer: @entity2


abstract: UNASSIGNED: BACKGROUND The present study aimed to assess the role of @entity3 polymorphism in drug-resistance in @entity1 by a meta-analysis. MATERIAL AND METHODS Databases were obtained from the Cochrane Library, MEDLINE, EMBASE, PubMed, Science Direct database, CNKI, and Wanfang up to October 2014. All the case-control association studies evaluating the role of @entity2 @entity3 in pharmacoresistance to anti- @entity1 drug (AED) were identified. RevMan 5.0 software was utilized to perform quantitative analyses in an allele model (C vs. T) and a genotype model (CC vs. CT+TT). RESULTS From the 189 potential studies, we included 28 articles for the meta-analysis, including 30 independent case-control studies involving 4124 drug-resistant @entity1 @entity0 and 4480 @entity1 @entity0 for whom drug treatment was effective. We excluded 164 studies because of duplication, lack of genotype data, and non-clinical research. We found that @entity3 polymorphism was not significantly associated with drug resistance in @entity1 , either in allele model (C vs. T: OR=1.07; 95%CI: 0.95-1.19) or in genotype model (CC vs. CT+TT: OR=1.05; 95%CI: 0.89-1.24, P=0.55). Subgroup analyses suggested that in Caucasian populations there are significant differences between resistance group (NR) and control group (R) in both allele model (C vs. T: OR=1.09; 95%CI: 1.00-1.18, P=0.05) and genotype model (CC vs. CT+TT: OR=1.20; 95%CI: 1.04-1.40, P=0.01). However, we did not find this association in Asian populations. CONCLUSIONS We conclude that the @entity2 @entity3 polymorphism may be a genetic marker for drug resistance in @entity1 in Caucasian populations.

title: @entity2 Gene XXXX Polymorphism and Drug Resistance in Epilepsy: Evidence Based on 8604 Subjects.

answer: @entity3


abstract: BACKGROUND: To determine the risk and predictors of progression of @entity1 ( @entity1 ) and other adverse events (AE) in adults with supracristal @entity4 ( @entity4 ). METHODS: Retrospective observational study of 62 adults with @entity4 followed at the Mayo Clinic from 1994 to 2013. Freedom from @entity1 progression was compared by age and racial groups (Asian vs non-Asian). Predictors of @entity1 progression were determined using Cox proportional hazard model. Composite AE endpoint was defined as @entity1 progression, @entity3 , @entity2 ( @entity2 ), and rupture of @entity2 . Risk of AE was compared between group 1 (no surgical intervention) and group 2 (surgical intervention). RESULTS: Sixty-two @entity0 aged 47(SD 12) years were followed for 13 (SD 5) years. Group 1=42/62 and group=20/62. Endpoint of @entity1 progression and @entity2 occurred in 13% and 20% respectively. Freedom from @entity1 progression for the entire cohort was 88%, 86% and 86% at 5, 10 and 15years respectively. Risk of @entity1 progression was significantly lower in @entity0 (aged  <=40years, p=0.008) but similar between Asians and non-Asians (p=0.57). Age  <=40years was an independent predictor of @entity1 progression (hazard ratio [HR] 3.5, 95% CI 2.3-5.4, p=0.001). Composite AE endpoint occurred in 33% and 40% of group1 and 2 cohorts respectively, p=0.69. CONCLUSION: Adults with @entity4 are at lower risk for @entity1 progression but higher risk for @entity2 formation compared to historical pediatric cohorts. Younger age was a predictor of @entity1 progression. Surgical intervention had no protective effect on complication rate.

title: XXXX in adults: Is it time for a paradigm shift?

answer: @entity4


abstract: BACKGROUND: Controlling @entity2 ( @entity2 ) associated with intermittent catheterization in geriatric @entity0 . AIM: After a local epidemiological study identified high rates of UTI, a multi-disciplinary working group implemented and evaluated corrective measures. METHODS: In 2009, a one-month prospective study measured the incidence of UTI, controlled for risk factors and exposure, in six geriatric hospitals. In 2010, a self-administered questionnaire on practices was administered to physicians and nurses working in these geriatric units. In 2011, the working group developed a multi-modal programme to: improve understanding of micturition, measurement of bladder volume and indications for catheter drainage; limit available medical devices; and improve prescription and traceability procedures. Detailed training was provided to all personnel on all sites. The epidemiological study was repeated in 2012 to assess the impact of the programme. FINDINGS: Over 1500 @entity0 were included in the 2009 study. The incidence of acquired @entity1 was 4.8%. The @entity1 rate was higher in @entity0 with intermittent catheters than in @entity0 with indwelling catheters (29.7 vs 9.9 UTI per 100 @entity0 , P  =  0.1013) which contradicts the literature. In 2010, the 269 responses to the questionnaire showed that staff did not consider catheterization to place @entity0 at risk of @entity1 , staff had poor knowledge of the recommended indications and techniques, and the equipment varied widely between units. Following implementation of the programme, the study was repeated in 2012 with over 1500 @entity0 . The frequency of UTI in @entity0 with intermittent catheters fell to rates in the published literature. CONCLUSION: Multi-modal programmes are an effective means to control UTI.

title: Controlling XXXX associated with intermittent bladder catheterization in geriatric hospitals.

answer: @entity2


abstract: OBJECTIVE: Determine if the pathophysiology of @entity6 , clinical presentation, cytology, and frozen section analysis signal an opportunity for less invasive parotid surgery and reduced morbidity. STUDY DESIGN: Retrospective review of 120 @entity0 parotidectomies identified 50 consecutive @entity6 . SETTING: Single surgeon, single institutional study. SUBJECTS AND METHODS: Surgeon performed ultrasound guided Fine Needle Aspiration (FNA) and intra-operative frozen section with nerve integrity monitoring were used in all cases. Partial superficial parotidectomy was performed in the initial 25 @entity0 and extracapsular dissection in the subsequent 25 @entity0 . RESULTs: Smoking history was acknowledged in 45/50 (90 percent) of @entity0 . The mean age was 63. Lower @entity3 and @entity5 occurred 23/50 (46 percent) and 11/50 (22 percent), respectively. @entity1 in the lower parotid pole occurred in 48/50 (96 percent). Frozen section diagnosis for @entity6 was confirmed by final pathology in all 50/50 (100 percent) @entity0 . Two of 50 @entity0 (8 percent) in the partial superficial parotidectomy group and no @entity0 in the extracapsular dissection group had transient @entity4 (p > 0.05). CONCLUSIONS: @entity6 presents with a high rate of symptomatic @entity2 , overwhelmingly in the lower parotid pole. Cytology largely excludes @entity1 . Frozen section analysis diagnosing @entity6 is highly specific in predicting final diagnosis. Minimally invasive approaches can be performed with confidence with extracapsular dissection or partial superficial parotidectomy resulting in potentially reduced morbidity.

title: Contemporary diagnosis and management of XXXX .

answer: @entity6


abstract: BACKGROUND: The effectiveness of continuous nationwide surveillance on healthcare-associated @entity0 should be investigated in each country. AIM: To assess the rate of device-associated @entity0 (DAIs) in intensive care units (ICUs) since the establishment of the Korean Nosocomial Infections Surveillance System (KONIS). METHODS: Nationwide data were obtained on the incidence rate of DAI in ICUs reported to KONIS by all participating hospitals. The three major DAIs were studied: @entity2 ( @entity2 ), central line-associated @entity0 (CABSI), and catheter-associated @entity1 (CAUTI). The pooled and year-wise incidence rates (cases per 1000 device-days) of these DAIs were determined for the period 2006 and 2012. In addition, data from institutions that had participated in KONIS for at least three consecutive years were analysed separately. FINDINGS: The number of ICUs participating in KONIS gradually increased from 76 in 2006 to 162 in 2012. Between 2006 and 2012, the incidence rate per 1000 device-days for @entity2 decreased significantly from 3.48 to 1.64 (F  =  11, P  <  0.01), for CAUTI the rate decreased non-significantly from 1.85 to 1.26 (F  =  2.02, P  =  0.07), and for CABSI the rate also decreased non-significantly from 3.4 to 2.57 (F  =  1.73, P  =  0.12). In the 132 ICUs that had participated in KONIS for at least three consecutive years, the @entity2 rate significantly decreased from the first year to third year (F  =  20.57, P  <  0.01), but the rates of CAUTI (F  =  1.06, P  =  0.35) and CABSI (F  =  1.39, P  =  0.25) did not change significantly. CONCLUSION: The decreased incidence rate of @entity2 in ICUs in Korea might be associated with the continuous prospective surveillance provided by KONIS.

title: Trends in the incidence rate of device-associated XXXX in intensive care units after the establishment of the Korean Nosocomial Infections Surveillance System.

answer: @entity0


abstract: OBJECTIVE: To explore the relationships between visceral adiposity index (VAI), @entity4 waist phenotype (HW phenotype) and @entity3 ( @entity3 ). METHODS: A cross-sectional study was conducted in Zhuhai City June-October 2012. A total of 2142 @entity0 were recruited. Logistic regression was used to evaluate the associations between VAI, HW phenotype and @entity3 . RESULTS: After adjustment for age, VAI was significantly associated with @entity3 (OR 2.16, 95  % CI 1.25-3.74, P  =  0.006) in @entity0 . Further adjusted for potential confounders, the association was still significant in @entity0 (OR 2.07, 95  % CI 1.17-3.64, P  =  0.01). However, the association was abolished when adding @entity1 and @entity2 to the model (OR 1.68, 95  % CI 0.92-3.06, P  =  0.09). The age-adjusted OR (95  % CI, P) of @entity3 associated with HW phenotype was 2.21 (1.29-3.76, 0.004) and 2.54 (1.53-4.22, <0.001) for @entity0 and @entity0 , respectively. Further adjusted for potential confounders, the associations were still significant in both subgroups. The OR for @entity3 was 2.41 (95  % CI 1.42-4.12, P  =  0.001) and 2.32 (95  % CI 1.31-4.11, P  =  0.004) for @entity0 and @entity0 , respectively. When further adjusted for @entity1 and @entity2 , the association of HW phenotype and @entity3 was significant (OR 1.88, 95  % CI 1.05-3.36, P  =  0.033) in @entity0 . However, the model is abolished in @entity0 (OR 1.50, 95  % CI 0.81-2.78, P  =  0.19). CONCLUSION: Our results suggest that both VAI and the HW phenotype might be useful clinical indicators of @entity3 in China for females but not for males. The HW phenotype associated more strongly with @entity3 , compared with VAI.

title: Visceral adiposity index, XXXX waist phenotype and @entity3 in a southern Chinese population: a cross-sectional study.

answer: @entity4


abstract: OBJECTIVE: To explore the relationships between visceral adiposity index (VAI), @entity4 waist phenotype (HW phenotype) and @entity3 ( @entity3 ). METHODS: A cross-sectional study was conducted in Zhuhai City June-October 2012. A total of 2142 @entity0 were recruited. Logistic regression was used to evaluate the associations between VAI, HW phenotype and @entity3 . RESULTS: After adjustment for age, VAI was significantly associated with @entity3 (OR 2.16, 95  % CI 1.25-3.74, P  =  0.006) in @entity0 . Further adjusted for potential confounders, the association was still significant in @entity0 (OR 2.07, 95  % CI 1.17-3.64, P  =  0.01). However, the association was abolished when adding @entity1 and @entity2 to the model (OR 1.68, 95  % CI 0.92-3.06, P  =  0.09). The age-adjusted OR (95  % CI, P) of @entity3 associated with HW phenotype was 2.21 (1.29-3.76, 0.004) and 2.54 (1.53-4.22, <0.001) for @entity0 and @entity0 , respectively. Further adjusted for potential confounders, the associations were still significant in both subgroups. The OR for @entity3 was 2.41 (95  % CI 1.42-4.12, P  =  0.001) and 2.32 (95  % CI 1.31-4.11, P  =  0.004) for @entity0 and @entity0 , respectively. When further adjusted for @entity1 and @entity2 , the association of HW phenotype and @entity3 was significant (OR 1.88, 95  % CI 1.05-3.36, P  =  0.033) in @entity0 . However, the model is abolished in @entity0 (OR 1.50, 95  % CI 0.81-2.78, P  =  0.19). CONCLUSION: Our results suggest that both VAI and the HW phenotype might be useful clinical indicators of @entity3 in China for females but not for males. The HW phenotype associated more strongly with @entity3 , compared with VAI.

title: Visceral adiposity index, @entity4 waist phenotype and XXXX in a southern Chinese population: a cross-sectional study.

answer: @entity3


abstract: UNASSIGNED: Electroconvulsive therapy (ECT) remains one of the most effective treatments of @entity2 . Unfortunately, some @entity0 report side effects, of which the most prominent are @entity3 . The immediate early gene Arc plays a critical role in the maintenance phase of long-term potentiation and consolidation of memory in the @entity1 brain. We recently observed increased methylation of the Arc promoter 24h after acute electroconvulsive stimulation (ECS) in @entity1 , which could cause decreased Arc expression and provide an explanation for the observed @entity3 . In the present study we investigated the methylation and expression changes of Arc at 48h post-ECS and determined the role of de-novo methylation in that process. We initially measured expression of DNA methyltransferases ( @entity5 and @entity7 ) and @entity8 , 4, 8, 16, 24, and 48h after a single ECS. Arc expression was increased approximately 10-fold at 1 and 4h after ECS, and subsequently decreased below sham levels. Four hours after ECS we also observed a significant increase in @entity7 expression, which was attenuated in a second experiment by the use of DNMT inhibitor @entity4 ( @entity4 ). We then investigated Arc gene expression and methylation changes at 48h post-ECS and we found a slightly reduced Arc expression in ECS-treated @entity1 as compared to sham. In animals that received @entity4 we observed a significant decrease in @entity7 expression and an increase of Arc expression in both ECS and sham groups. The same tendency for reduced Arc expression after ECS, as compared to sham was observed despite the blocking of DNA methylation with @entity4 . The DNA methylation as measured by pyrosequencing is decreased 48h post-ECS both in the promoter and intragenic regions as a response to ECS regardless of the treatment with @entity4 . Overall the results suggest that DNA methylation is involved in regulating Arc expression but is not the causal mechanism responsible for reducing Arc expression after ECS. We speculate that the decrease is caused by ECS-induced @entity6 upregulation and decreased H3 acetylation at the Arc promoter.

title: Epigenetic regulation of XXXX and Arc gene expression after electroconvulsive stimulation in the @entity1 .

answer: @entity7


abstract: UNASSIGNED: Electroconvulsive therapy (ECT) remains one of the most effective treatments of @entity2 . Unfortunately, some @entity0 report side effects, of which the most prominent are @entity3 . The immediate early gene Arc plays a critical role in the maintenance phase of long-term potentiation and consolidation of memory in the @entity1 brain. We recently observed increased methylation of the Arc promoter 24h after acute electroconvulsive stimulation (ECS) in @entity1 , which could cause decreased Arc expression and provide an explanation for the observed @entity3 . In the present study we investigated the methylation and expression changes of Arc at 48h post-ECS and determined the role of de-novo methylation in that process. We initially measured expression of DNA methyltransferases ( @entity5 and @entity7 ) and @entity8 , 4, 8, 16, 24, and 48h after a single ECS. Arc expression was increased approximately 10-fold at 1 and 4h after ECS, and subsequently decreased below sham levels. Four hours after ECS we also observed a significant increase in @entity7 expression, which was attenuated in a second experiment by the use of DNMT inhibitor @entity4 ( @entity4 ). We then investigated Arc gene expression and methylation changes at 48h post-ECS and we found a slightly reduced Arc expression in ECS-treated @entity1 as compared to sham. In animals that received @entity4 we observed a significant decrease in @entity7 expression and an increase of Arc expression in both ECS and sham groups. The same tendency for reduced Arc expression after ECS, as compared to sham was observed despite the blocking of DNA methylation with @entity4 . The DNA methylation as measured by pyrosequencing is decreased 48h post-ECS both in the promoter and intragenic regions as a response to ECS regardless of the treatment with @entity4 . Overall the results suggest that DNA methylation is involved in regulating Arc expression but is not the causal mechanism responsible for reducing Arc expression after ECS. We speculate that the decrease is caused by ECS-induced @entity6 upregulation and decreased H3 acetylation at the Arc promoter.

title: Epigenetic regulation of @entity7 and Arc gene expression after electroconvulsive stimulation in the XXXX .

answer: @entity1


abstract: AIMS: @entity4 ( @entity4 ) is associated with changes in energy metabolism of the heart, as well as in extra-cardiac organs such as the skeletal muscles. @entity2 is a common complication and is associated with poor prognosis. Branched-chain @entity7 (BCAAs) reportedly improve @entity8 and @entity0 . We tested the hypothesis that @entity6 ameliorates @entity4 with @entity2 . MAIN METHODS: We used Dahl salt-sensitive (DS) @entity1 fed a high-salt diet as a model of @entity4 . DS @entity1 fed a low-salt diet were used as a control. @entity6 were administered in drinking water from 11weeks of age, when @entity5 was established but the cardiac function was preserved. Survival and the cardiac function were monitored, and animals were sacrificed at 21weeks of age and analyzed. KEY FINDINGS: In @entity4 @entity1 , @entity6 treatment decreased the heart rate, preserved the cardiac function, and prolonged survival. @entity6 also prevented body @entity3 , associated with preservation of the skeletal muscle weight. Moreover, gene expression related to mitochondrial biogenesis and function was increased with @entity6 in skeletal muscles. SIGNIFICANCE: @entity6 preserved the body weight and cardiac function and prolonged survival in @entity4 @entity1 . The expression of genes involved in mitochondrial biogenesis and function in skeletal muscles was increased by @entity6 .

title: Branched-chain @entity7 ameliorate XXXX with @entity2 in @entity1 .

answer: @entity4


abstract: AIMS: @entity4 ( @entity4 ) is associated with changes in energy metabolism of the heart, as well as in extra-cardiac organs such as the skeletal muscles. @entity2 is a common complication and is associated with poor prognosis. Branched-chain @entity7 (BCAAs) reportedly improve @entity8 and @entity0 . We tested the hypothesis that @entity6 ameliorates @entity4 with @entity2 . MAIN METHODS: We used Dahl salt-sensitive (DS) @entity1 fed a high-salt diet as a model of @entity4 . DS @entity1 fed a low-salt diet were used as a control. @entity6 were administered in drinking water from 11weeks of age, when @entity5 was established but the cardiac function was preserved. Survival and the cardiac function were monitored, and animals were sacrificed at 21weeks of age and analyzed. KEY FINDINGS: In @entity4 @entity1 , @entity6 treatment decreased the heart rate, preserved the cardiac function, and prolonged survival. @entity6 also prevented body @entity3 , associated with preservation of the skeletal muscle weight. Moreover, gene expression related to mitochondrial biogenesis and function was increased with @entity6 in skeletal muscles. SIGNIFICANCE: @entity6 preserved the body weight and cardiac function and prolonged survival in @entity4 @entity1 . The expression of genes involved in mitochondrial biogenesis and function in skeletal muscles was increased by @entity6 .

title: Branched-chain XXXX ameliorate @entity4 with @entity2 in @entity1 .

answer: @entity7


abstract: AIMS: @entity4 ( @entity4 ) is associated with changes in energy metabolism of the heart, as well as in extra-cardiac organs such as the skeletal muscles. @entity2 is a common complication and is associated with poor prognosis. Branched-chain @entity7 (BCAAs) reportedly improve @entity8 and @entity0 . We tested the hypothesis that @entity6 ameliorates @entity4 with @entity2 . MAIN METHODS: We used Dahl salt-sensitive (DS) @entity1 fed a high-salt diet as a model of @entity4 . DS @entity1 fed a low-salt diet were used as a control. @entity6 were administered in drinking water from 11weeks of age, when @entity5 was established but the cardiac function was preserved. Survival and the cardiac function were monitored, and animals were sacrificed at 21weeks of age and analyzed. KEY FINDINGS: In @entity4 @entity1 , @entity6 treatment decreased the heart rate, preserved the cardiac function, and prolonged survival. @entity6 also prevented body @entity3 , associated with preservation of the skeletal muscle weight. Moreover, gene expression related to mitochondrial biogenesis and function was increased with @entity6 in skeletal muscles. SIGNIFICANCE: @entity6 preserved the body weight and cardiac function and prolonged survival in @entity4 @entity1 . The expression of genes involved in mitochondrial biogenesis and function in skeletal muscles was increased by @entity6 .

title: Branched-chain @entity7 ameliorate @entity4 with XXXX in @entity1 .

answer: @entity2


abstract: AIMS: @entity4 ( @entity4 ) is associated with changes in energy metabolism of the heart, as well as in extra-cardiac organs such as the skeletal muscles. @entity2 is a common complication and is associated with poor prognosis. Branched-chain @entity7 (BCAAs) reportedly improve @entity8 and @entity0 . We tested the hypothesis that @entity6 ameliorates @entity4 with @entity2 . MAIN METHODS: We used Dahl salt-sensitive (DS) @entity1 fed a high-salt diet as a model of @entity4 . DS @entity1 fed a low-salt diet were used as a control. @entity6 were administered in drinking water from 11weeks of age, when @entity5 was established but the cardiac function was preserved. Survival and the cardiac function were monitored, and animals were sacrificed at 21weeks of age and analyzed. KEY FINDINGS: In @entity4 @entity1 , @entity6 treatment decreased the heart rate, preserved the cardiac function, and prolonged survival. @entity6 also prevented body @entity3 , associated with preservation of the skeletal muscle weight. Moreover, gene expression related to mitochondrial biogenesis and function was increased with @entity6 in skeletal muscles. SIGNIFICANCE: @entity6 preserved the body weight and cardiac function and prolonged survival in @entity4 @entity1 . The expression of genes involved in mitochondrial biogenesis and function in skeletal muscles was increased by @entity6 .

title: Branched-chain @entity7 ameliorate @entity4 with @entity2 in XXXX .

answer: @entity1


abstract: BACKGROUND AND PURPOSE: The hippocampus plays a role in the verbal and spatial memory processing, learning, and emotions. The purpose of this study was to determine clinical, etiological, and radiological features of isolated @entity15 . METHODS: We reviewed, 6800 @entity0 with first-ever @entity2 included in our @entity2 Registry between 2004 and 2014. Among them we studied 19 @entity0 with an acute isolated hippocampal @entity11 confirmed by MRI. RESULTS: Among 6800 @entity0 , 19 @entity0 (0.03%) showed @entity4 in the hippocampal artery territory, allowing us to delineate 5 variant distributions; (1) anterior @entity15 (4 @entity0 [21%]) were present with altered consciousness, transient @entity13 , and @entity16 with @entity14 . (2) Posterior @entity15 (3 @entity0 [16%]) developed @entity12 and dullness at @entity2 onset, @entity10 , @entity14 . (3) Unilateral complete @entity15 were present (4 @entity0 [21%]) with @entity10 , object specific @entity13 , intense mood states changes as well as impulsivity or @entity7 . @entity14 were found in all @entity0 . (4) Bilateral @entity15 (3 @entity0 [16%]) had @entity3 and @entity14 in all @entity0 . All @entity0 had difficulties retrieving specific autobiographical events and retrieving recent memory, and @entity5 . Hippocampal @entity6 was observed in 2 @entity0 with severe immediate, delayed @entity5 , @entity1 in responding to feedback and error correction with dull and aimless appearance lasting several months. (5) Small circumscribed (punctiform) @entity15 (5 @entity0 [26%]) showed @entity12 or dullness sensation and difficulties finding words or objects that they use everyday. Cardioembolism (10; 53%) and @entity8 (6; 32%) were the main @entity2 mechanisms. CONCLUSIONS: We described topographic patterns of hippocampal @entity11 with distinct manifestations and etiologies. We thought that different patterns of @entity15 are the result of variation in hippocampal arterial supply or reflect a source of @entity9 .

title: Isolated XXXX : Vascular and neuropsychological findings.

answer: @entity15


abstract: UNASSIGNED: We report our institution's experience with adult @entity0 who underwent surgery for intramedullary spinal cord @entity3 . Spine involvement of @entity3 is rare, representing 7.5% of all intramedullary gliomas and 1-3% of all @entity6 . We performed a retrospective review of five male @entity0 with intramedullary spinal cord @entity3 who underwent surgical resection from 1990 to 2014. Demographic, operative, and postoperative factors were recorded. The median age at treatment was 31years (range: 18-61) and all @entity0 presented with @entity5 . Two had prior surgical resection of an intramedullary World Health Organization Grade III anaplastic @entity2 with adjuvant chemoradiation. All @entity1 were present in the cervical (n=2; 40%) or @entity4 (n=3; 60%) spine, spanning a median of three levels (range: 2-4). Gross total resection was achieved in three @entity0 (60%), and there were no intraoperative mortalities or complications. Although one had improvement in his neurological status postoperatively, all five @entity0 died with a median time to death of 20months (range: 2-31). Adult intramedullary spinal cord @entity3 is rare, and despite aggressive treatment, prognosis is poor, with a median survival in our series of only 20months. New treatment strategies are necessary to improve survival in this @entity0 population.

title: Poor prognosis despite aggressive treatment in adults with intramedullary spinal cord XXXX .

answer: @entity3


abstract: OBJECTIVES: Adjuvant @entity3 with or without chemoradiation is a standard therapeutic option for @entity0 with resected @entity6 . The feasibility and @entity4 of @entity3 with @entity8 before and after @entity10 ( @entity10 )-based chemoradiation in the adjuvant pancreatic and @entity1 setting were investigated. METHODS: After a curative-intent resection, eligible @entity0 with @entity1 were treated with two cycles of @entity3 and @entity8 followed by @entity10 -based chemoradiation. Four weeks after completing chemoradiation, two cycles of @entity3 and @entity8 were administered. The primary endpoint was the incidence of severe @entity4 . Secondary endpoints included disease-free survival (DFS) and @entity9 ( @entity9 ). RESULTS: Fifty @entity0 with @entity1 were enrolled. Twenty-nine @entity0 had @entity6 whereas 21 @entity0 had biliary tract or @entity1 . There was one @entity5 as a result of @entity2 , and 15% of @entity0 experienced grade 3 or greater non-haematological @entity4 . The median DFS and @entity9 for @entity0 with @entity6 were 9.6 and 17 months, respectively, and for those with resected @entity7 were 12 and 23 months, respectively. CONCLUSIONS: This combination of @entity3 and @entity8 with chemoradiation is feasible and tolerable in the adjuvant setting. Future studies utilizing a different @entity3 / @entity11 combination and schedule may be appropriate in the adjuvant treatment of both @entity6 and @entity1 .

title: A phase II study of adjuvant XXXX plus @entity8 followed by concurrent chemoradation in resected pancreaticobiliary carcinoma.

answer: @entity3


abstract: OBJECTIVES: Adjuvant @entity3 with or without chemoradiation is a standard therapeutic option for @entity0 with resected @entity6 . The feasibility and @entity4 of @entity3 with @entity8 before and after @entity10 ( @entity10 )-based chemoradiation in the adjuvant pancreatic and @entity1 setting were investigated. METHODS: After a curative-intent resection, eligible @entity0 with @entity1 were treated with two cycles of @entity3 and @entity8 followed by @entity10 -based chemoradiation. Four weeks after completing chemoradiation, two cycles of @entity3 and @entity8 were administered. The primary endpoint was the incidence of severe @entity4 . Secondary endpoints included disease-free survival (DFS) and @entity9 ( @entity9 ). RESULTS: Fifty @entity0 with @entity1 were enrolled. Twenty-nine @entity0 had @entity6 whereas 21 @entity0 had biliary tract or @entity1 . There was one @entity5 as a result of @entity2 , and 15% of @entity0 experienced grade 3 or greater non-haematological @entity4 . The median DFS and @entity9 for @entity0 with @entity6 were 9.6 and 17 months, respectively, and for those with resected @entity7 were 12 and 23 months, respectively. CONCLUSIONS: This combination of @entity3 and @entity8 with chemoradiation is feasible and tolerable in the adjuvant setting. Future studies utilizing a different @entity3 / @entity11 combination and schedule may be appropriate in the adjuvant treatment of both @entity6 and @entity1 .

title: A phase II study of adjuvant @entity3 plus XXXX followed by concurrent chemoradation in resected pancreaticobiliary carcinoma.

answer: @entity8


abstract: @entity3 ( @entity4 ) is almost entirely eliminated by the kidneys and has a terminal plasma half-life (t1/2) of 2 to 3 hr in subjects with normal renal function. To determine the drug's kinetics and tolerance in @entity0 with severe @entity1 , six anuric subjects on long-term hemodialysis were studied. Each received a 1-hr infusion of 2.5 mg/kg IV @entity4 . The kinetics are well described by a two-compartment open model. @entity4 terminal plasma t 1/2 and the total body clearance were 19.5 +/- 5.9 hr (mean +/- SD) and 28.6 +/- 9.5 ml/min/1.73 m2. Peak (end of infusion) and 8- and 24-hr plasma @entity4 concentrations were 37.5 +/- 23.3, 10.3 +/- 2.9, and 6.4 +/- 2.4 microM. Approximately 48 hr after the start of the infusion the subjects were hemodialyzed for 6 hr. The pre- and posthemodialysis @entity4 plasma levels were 2.74 +/- 1.38 and 1.11 +/- 0.60 microM. The terminal @entity4 t1/2 during hemodialysis was 5.7 +/- 0.85 hr. During hemodialysis paired arterial and venous samples showed that @entity4 was readily dialyzed, with a mean coefficient of extraction of 0.45 +/- 0.12. The dialysis clearance of @entity3 was 81.8 +/- 12.6 ml/min. None of the @entity0 had any @entity4 -related adverse effects. Since @entity4 elimination is markedly reduced in @entity2 and because @entity4 is readily hemodialyzible, dosage modification are needed to avoid cumulation and to replace dialyzed drug.

title: XXXX kinetics in @entity2 .

answer: @entity3


abstract: @entity3 ( @entity4 ) is almost entirely eliminated by the kidneys and has a terminal plasma half-life (t1/2) of 2 to 3 hr in subjects with normal renal function. To determine the drug's kinetics and tolerance in @entity0 with severe @entity1 , six anuric subjects on long-term hemodialysis were studied. Each received a 1-hr infusion of 2.5 mg/kg IV @entity4 . The kinetics are well described by a two-compartment open model. @entity4 terminal plasma t 1/2 and the total body clearance were 19.5 +/- 5.9 hr (mean +/- SD) and 28.6 +/- 9.5 ml/min/1.73 m2. Peak (end of infusion) and 8- and 24-hr plasma @entity4 concentrations were 37.5 +/- 23.3, 10.3 +/- 2.9, and 6.4 +/- 2.4 microM. Approximately 48 hr after the start of the infusion the subjects were hemodialyzed for 6 hr. The pre- and posthemodialysis @entity4 plasma levels were 2.74 +/- 1.38 and 1.11 +/- 0.60 microM. The terminal @entity4 t1/2 during hemodialysis was 5.7 +/- 0.85 hr. During hemodialysis paired arterial and venous samples showed that @entity4 was readily dialyzed, with a mean coefficient of extraction of 0.45 +/- 0.12. The dialysis clearance of @entity3 was 81.8 +/- 12.6 ml/min. None of the @entity0 had any @entity4 -related adverse effects. Since @entity4 elimination is markedly reduced in @entity2 and because @entity4 is readily hemodialyzible, dosage modification are needed to avoid cumulation and to replace dialyzed drug.

title: @entity3 kinetics in XXXX .

answer: @entity2


abstract: UNASSIGNED: @entity1 outbreak is a major global health care problem. However, current @entity2 risk assessments may be compromised by uncertainties in @entity2 detection methods, infectious dose, and strain infectivity. These limitations may place public health at significant risk, leading to significant monetary losses in health care. However, there are still unmet needs for its rapid identification and monitoring of legionellae in water systems. Therefore, in the present study, a primer set was designed based on a LysR-type transcriptional regulator (LTTR) family protein gene of @entity2 because it was found that this gene is structurally diverse among species through BLAST searches. The specificity of the primer set was evaluated using genomic DNA from 6 strains of @entity0 , 5 type strains of other related @entity2 species, and other 29 reference pathogenic bacteria. The primer set used in the PCR assay amplified a 264-bp product for only targeted six strains of @entity0 . The assay was also able to detect at least 1.39   *   10(3) copies/ l of cloned amplified target DNA using purified DNA or 7.4   *   10(0) colony-forming unit per reaction when using calibrated cell suspension. In addition, the sensitivity and specificity of this assay were confirmed by successful detection of @entity0 in environmental water samples.

title: Improved PCR assay for the species-specific identification and quantitation of XXXX in water.

answer: @entity0


abstract: BACKGROUND: In the USA, ethnic disparities in @entity2 persist after accounting for known risk factors. Ambient air pollution is associated with increased levels of @entity2 and differs in the USA by race/ethnicity. We estimated the influence of ambient air pollution exposure to ethnic differences in common carotid @entity1 ( @entity1 ). METHODS: We cross-sectionally studied 6347 Caucasian-American, African-American, Hispanic and Chinese adults across 6 US cities in 2000-2002. Annual ambient air pollution concentrations (fine particulate matter [PM2.5] and @entity4 of @entity3 [NOX]) were estimated at each @entity0 's residence. @entity1 was assessed by ultrasound. RESULTS: The mean @entity1 was 19.4 and 37.6    m smaller for Hispanic @entity0 and @entity0 , 53.6 and 7.1    m smaller for Chinese @entity0 and @entity0 , and 23.4 and 38.7    m higher for African-American @entity0 and @entity0 compared with Caucasian-American @entity0 and @entity0 . After adjustment for PM2.5, the differences in @entity1 remained similar for Hispanic and African-American @entity0 but was even more negative for Chinese @entity0 (mean @entity1 difference of -58.4    m for @entity0 and -15.7    m for @entity0 ) compared with Caucasian-American @entity0 . The @entity1 difference in Chinese @entity0 compared with Caucasian-American @entity0 related to their higher PM2.5 exposures was 4.8    m (95% CI 0.2 to 10.8) for @entity0 and 8.6    m (95% CI 3.4 to 15.3) for @entity0 . NOX was not related to ethnic differences in @entity1 . CONCLUSIONS: The smaller carotid @entity1 levels in Chinese @entity0 were even smaller after accounting for higher PM2.5 concentrations in Chinese @entity0 compared with Caucasian-American @entity0 . Air pollution was not related to @entity1 differences in African-American and Hispanic @entity0 compared with Caucasian-American @entity0 .

title: Ambient air pollution and racial/ethnic differences in carotid XXXX in the Multi-Ethnic Study of @entity2 (MESA).

answer: @entity1


abstract: BACKGROUND: In the USA, ethnic disparities in @entity2 persist after accounting for known risk factors. Ambient air pollution is associated with increased levels of @entity2 and differs in the USA by race/ethnicity. We estimated the influence of ambient air pollution exposure to ethnic differences in common carotid @entity1 ( @entity1 ). METHODS: We cross-sectionally studied 6347 Caucasian-American, African-American, Hispanic and Chinese adults across 6 US cities in 2000-2002. Annual ambient air pollution concentrations (fine particulate matter [PM2.5] and @entity4 of @entity3 [NOX]) were estimated at each @entity0 's residence. @entity1 was assessed by ultrasound. RESULTS: The mean @entity1 was 19.4 and 37.6    m smaller for Hispanic @entity0 and @entity0 , 53.6 and 7.1    m smaller for Chinese @entity0 and @entity0 , and 23.4 and 38.7    m higher for African-American @entity0 and @entity0 compared with Caucasian-American @entity0 and @entity0 . After adjustment for PM2.5, the differences in @entity1 remained similar for Hispanic and African-American @entity0 but was even more negative for Chinese @entity0 (mean @entity1 difference of -58.4    m for @entity0 and -15.7    m for @entity0 ) compared with Caucasian-American @entity0 . The @entity1 difference in Chinese @entity0 compared with Caucasian-American @entity0 related to their higher PM2.5 exposures was 4.8    m (95% CI 0.2 to 10.8) for @entity0 and 8.6    m (95% CI 3.4 to 15.3) for @entity0 . NOX was not related to ethnic differences in @entity1 . CONCLUSIONS: The smaller carotid @entity1 levels in Chinese @entity0 were even smaller after accounting for higher PM2.5 concentrations in Chinese @entity0 compared with Caucasian-American @entity0 . Air pollution was not related to @entity1 differences in African-American and Hispanic @entity0 compared with Caucasian-American @entity0 .

title: Ambient air pollution and racial/ethnic differences in carotid @entity1 in the Multi-Ethnic Study of XXXX (MESA).

answer: @entity2


abstract: UNASSIGNED: Primary @entity3 is a rare disease, and no standard treatments have been defined yet. In this study, 38 consecutive @entity0 from single center were reviewed. Among 25 @entity0 with @entity1 , radical surgery were performed in 12 @entity0 , and the other 13 @entity0 had chemotherapy combined with (7 @entity0 ) or without (6 @entity0 ) radiotherapy. No significant difference in @entity4 ( @entity4 ) was found between @entity0 who received surgery or not; however, @entity0 treated with chemotherapy had superior progression-free survival (PFS) than those treated with upfront surgery (P   =   0.032). Among the 12 @entity0 who received radical surgery, 7 were given adjuvant chemotherapy and 1 @entity0 had consolidation radiotherapy. No significant differences in PFS and @entity4 exist between those who received adjuvant treatment or not (P   >   0.05). For @entity0 who received chemotherapy, PFS and @entity4 were significantly better for those treated with @entity2 -based therapy than @entity5 -based therapy. At a median follow-up time of 61.1  months, 5- and 10-year PFS rate was 70.0 and 43.0  %, respectively, and 5- and 10-year @entity4 rate was both 81.0  %. In conclusion, we confirmed the indolent behavior and favorable outcome of this disease. In order to preserve lung function and reduce the risks associated with surgery, radiotherapy or rituximab in combination with alkylating drug-based chemotherapy should be considered as first-line option for @entity3 .

title: Radical surgery may be not an optimal treatment approach for XXXX .

answer: @entity3


abstract: Between 1971 and 1981, 74 @entity0 with @entity8 vera were treated with pipobroman using a high-dose induction, low-dose maintenance regimen. Complete remission was achieved in 51 of 54 previously untreated @entity0 (94.4%) and in 17 of 20 @entity0 (85%) previously treated wih radioactive @entity7 (32 p) and @entity5 . The earliest modifications were noted on day 16, and on the average, blood counts were normal by day 45. Thirty percent of the @entity0 relapsed, the mean duration of the remission being 17.5 mo. Following recurrence pipobroman was consistently effective in the same doses but the mean duration of the next remissions was 10 mo. Transient @entity3 and @entity2 occurred in 8% and 7% of @entity0 , respectively, during initial phase, and @entity1 was noted in 3 @entity0 . @entity9 was noted in 20% of @entity0 during maintenance phase. Three cases of @entity6 and 3 cases of osteomyelosclerosis were recorded, all occurring in @entity0 who had previously received 32 p and/or @entity5 . No @entity4 were seen among @entity0 treated with @entity10 alone; follow-up exceeded 6 yr for 20 @entity0 and the median follow-up period was 3.6 yr. Pipobroman appears safer than other alkylating agents; it is as effective as 32 p and works more quickly. Longer follow-up will be required to evaluate the drug's oncogenic potential, which is still not known.

title: Pipobroman therapy of XXXX vera.

answer: @entity8


abstract: 1. @entity0 exposed to 2.0 mg/1. @entity7 ( @entity7 ) in the inspired air for 2 days, 4 h a day, showed a 13% decrease in their brain @entity3 concentration and a 16% increase in their brain @entity2 concentration.2. After exposure for 5 or 10 days there was a further decrease in the concentration of @entity3 in the brain, but brain @entity2 returned to the control level.3. In animals treated intraperitoneally with 2.0 mg/kg @entity4 and exposed 2 and 3 days later to 2.0 mg/1. CS(2) for 4 h per day, the brain @entity2 concentration showed a 77% increase compared with the unexposed reserpinized animals, but the @entity3 concentration remained unchanged.4. The @entity2 concentrations in the adrenals after 10 days' exposure to 2.0 mg/1. CS(2) were 67% to 100% higher than in the control animals. In reserpinized @entity0 , 2 days' exposure to @entity7 nearly trebled the @entity2 content of adrenals.5. Exposure to @entity7 had no effect on the @entity1 concentration in the brain, and there was no change in the brain @entity6 ( @entity6 ) activity. @entity1 in the brain showed a 30 to 96% increase in concentration and @entity6 activity, using @entity8 as substrate, showed an approximately 5% increase 0.5 to 2 h after the subcutaneous administration of 500 mg/kg @entity5 .6. CS(2) at 10(-2)M or lower concentrations had no inhibitory effect on the brain @entity6 activity in vitro. @entity5 inhibited @entity6 at 10(-2)M, but not at 10(-3)M or lower concentrations.

title: The effects of XXXX exposure on brain catecholamines in @entity0 .

answer: @entity7


abstract: 1. @entity0 exposed to 2.0 mg/1. @entity7 ( @entity7 ) in the inspired air for 2 days, 4 h a day, showed a 13% decrease in their brain @entity3 concentration and a 16% increase in their brain @entity2 concentration.2. After exposure for 5 or 10 days there was a further decrease in the concentration of @entity3 in the brain, but brain @entity2 returned to the control level.3. In animals treated intraperitoneally with 2.0 mg/kg @entity4 and exposed 2 and 3 days later to 2.0 mg/1. CS(2) for 4 h per day, the brain @entity2 concentration showed a 77% increase compared with the unexposed reserpinized animals, but the @entity3 concentration remained unchanged.4. The @entity2 concentrations in the adrenals after 10 days' exposure to 2.0 mg/1. CS(2) were 67% to 100% higher than in the control animals. In reserpinized @entity0 , 2 days' exposure to @entity7 nearly trebled the @entity2 content of adrenals.5. Exposure to @entity7 had no effect on the @entity1 concentration in the brain, and there was no change in the brain @entity6 ( @entity6 ) activity. @entity1 in the brain showed a 30 to 96% increase in concentration and @entity6 activity, using @entity8 as substrate, showed an approximately 5% increase 0.5 to 2 h after the subcutaneous administration of 500 mg/kg @entity5 .6. CS(2) at 10(-2)M or lower concentrations had no inhibitory effect on the brain @entity6 activity in vitro. @entity5 inhibited @entity6 at 10(-2)M, but not at 10(-3)M or lower concentrations.

title: The effects of @entity7 exposure on brain catecholamines in XXXX .

answer: @entity0


abstract: PURPOSE: The National Breast and @entity1 Early Detection Program (NBCCEDP) enrolls asymptomatic @entity0 for @entity1 screening and symptomatic @entity0 for diagnostic services. This study describes the results of mammograms provided by the NBCCEDP, by examination indication (screening or diagnostic), and by age group. METHODS: For the first NBCCEDP-funded mammogram received during 2009-2012, we calculated age-specific percentages of abnormal findings, rates of follow-up testing, and invasive and in situ breast @entity1 diagnoses per 1,000  mammograms. Logistic regression was used to estimate the odds for each of these outcomes by examination indication. RESULTS: The NBCCEDP provided 941,649 screening, 175,310 diagnostic, and 30,434 unknown indication mammograms to 1,147,393 @entity0 . The percentage with abnormal mammograms was higher for diagnostic mammograms (40.1  %) than for screening mammograms (15.5  %). Compared with @entity0 aged 40-49  years, fewer @entity0 aged 50-64  years had abnormal results for screening (13.7 vs. 19.7  %) and diagnostic mammograms (37.7 vs. 42.7  %). Follow-up rates per 1,000  mammograms were lower among @entity0 aged 50-64 compared to those aged 40-49 (screening: 143.9 vs. 207.5; diagnostic: 645.3 vs. 760.9); biopsy rates exhibited a similar pattern (screening: 24.1 vs. 32.9; diagnostic: 167.7 vs. 169.7). For screening mammograms, older @entity0 had more @entity1 detected than younger @entity0 (invasive: 3.6 vs. 2.2; in situ: 2.3 vs. 2.0). Similarly, for diagnostic mammograms, @entity1 detection was higher for older @entity0 (invasive: 67.8 vs. 36.6; in situ: 17.4 vs. 11.1). CONCLUSIONS: Abnormal mammograms and diagnostic follow-up procedures were less frequent in @entity0 aged 50-64  years compared to @entity0 aged 40-49  years, while breast @entity1 detection was higher, regardless of indication for the mammogram. Some of these differences between age groups were greater for screening mammograms than for diagnostic mammograms. @entity1 detection rates were higher for diagnostic mammograms compared with screening mammograms. These findings support the NBCCEDP's priority of serving @entity0 aged 50-64  years and providing both screening and diagnostic mammograms.

title: Clinical outcomes of mammography in the National Breast and XXXX Early Detection Program, 2009-2012.

answer: @entity1


abstract: PURPOSE: To investigate the performance of a new device that uses the STRATA polytetrafluoroethylene graft material and a mechanism that provides active proximal sealing in order to prevent @entity6 during @entity3 repair (EVAR). METHODS: Between April 2013 and July 2014, 21 consecutive @entity0 (all @entity0 ; median age 71 years, range 60-84 years) with @entity5 (median diameter 5.9 cm, range 4.9-7.8 cm) and suitable anatomy were offered elective EVAR using the AFX endograft. These @entity0 had an irregular, conical, tapered, or bulging proximal neck, for which this specific device was considered appropriate. @entity3 exclusion and incidence of @entity6 were the primary outcomes; secondary outcomes included mortality, morbidity, migration, and other graft-related complications. RESULTS: Primary technical success was 90%; 2 intraoperative type Ia endoleaks due to low endograft deployment were treated with additional proximal cuffs. During a median follow-up of 10 months (range 2-15 months), no @entity6 was observed. One @entity6 was encountered, with no associated sac enlargement. There was no stent-graft migration or any other device-related complication. One @entity0 had a nonfatal @entity4 and another developed @entity1 requiring transient dialysis. No @entity2 occurred. CONCLUSION: In this early experience, this newly available device appears to be safe and efficient in providing seal along irregularly shaped necks over the short term.

title: Active proximal sealing in the endovascular repair of XXXX : early results with a new stent-graft.

answer: @entity5


abstract: BACKGROUND: There is evidence that both @entity0 @entity1 and their partners are affected emotionally, when facing a @entity0 . Several couple interventions have been evaluated, but there is a need for couple intervention studies with a clear theoretical basis and a strong design. The Hand in Hand intervention is designed to enhance interdependent coping in the couples and to address @entity1 and partners that are both initially distressed and non-distressed. METHODS: The Hand in Hand study is a randomised controlled trial among 199 @entity0 @entity1 and their partners. Couples were randomised to 4-8 couple sessions with a psychologist in addition to usual care, or to usual care only, approximately 2 months after the @entity1 ' primary surgery date. The intervention was delivered within 3 months, and outcomes were assessed prior to randomisation and 5 and 10 months after primary surgery date. The primary outcome is @entity1 ' @entity2 at the 5-month follow-up measured by the Impact of Event Scale. Secondary outcomes are assessed for both @entity0 @entity1 and partners. These outcomes are: general distress, symptoms of @entity3 and @entity4 , health-related quality of life and measures of dyadic adjustment, intimacy and partner involvement. @entity2 is also assessed for partners. Eligible @entity1 were @entity1   >=    18 years newly diagnosed with primary @entity0 , cohabiting with a male partner, having no previous @entity2 diagnoses, receiving no neo-adjuvant treatment, having no history of hospitalisation due to @entity5 , and able to read and speak Danish. Partners were eligible if they could read and speak Danish and were   >=    18 years. DISCUSSION: This study investigates the effect of an attachment-oriented psychological intervention for @entity0 @entity1 and their partners. The intervention has a theoretical framework and a strong design. If proven effective, this intervention would be helpful in optimising psychosocial care and rehabilitation of couples coping with @entity0 . TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01368380.

title: Attachment-oriented psychological intervention for couples facing XXXX : protocol of a randomised controlled trial.

answer: @entity0


abstract: OBJECTIVE: Using a retrospective cohort study, the mean length of hospital stay (LoS) and total per- @entity0 expenditure for @entity3 requiring admission to hospital were estimated. In a separate matched retrospective cohort study, the effect of inpatient @entity3 on LoS, expenditure, and risk of all-cause mortality while admitted was investigated. METHODS: The cohorts consisted of @entity0 aged >= 18   years with a diagnosis of @entity2 1 or 2 @entity1 between January 1, 2002 and October 30, 2012 in the Clinical Practice Research Datalink database, who had initiated insulin treatment and had a recording of @entity3 in the same period. In the matched retrospective cohort study, exposed @entity0 (who experienced @entity3 in hospital) were case-matched with @entity0 who did not experience @entity3 during admission (unexposed). Generalized linear regression was used to estimate LoS. Risk of all-cause mortality was evaluated via logistic regression. RESULTS: In the retrospective cohort study (1131 @entity0 ), mean LoS was 5.46 (95% CI 4.62  to 6.45) days for @entity2 1 @entity1 , and 5.04 (95% CI 4.46 to 5.71) days for @entity2 2 @entity1 . Mean cost per admission was   1034 (95% CI   855 to   1253). In the matched retrospective cohort study (1079 pairs of @entity0 ), exposed @entity0 had a mean LoS of 11.91   days (95% CI 10.96  to 12.94   days) versus 4.80 (95% CI 4.41  to 5.23) for unexposed @entity0 , p<0.0001. Exposed @entity0 had a higher mortality risk compared with unexposed @entity0 (OR 1.439 (95% CI 1.060to 1.952), p=0.0195). Total average per- @entity0 cost for exposed @entity0 was GBP (  )2235, 40% (p<0.0001) higher than total average admission cost in unexposed @entity0 . CONCLUSIONS: @entity3 has a significant negative impact on @entity0 outcomes, healthcare resource use, and expenditure.

title: Healthcare resource implications of XXXX -related hospital admissions and inpatient @entity3 : retrospective record-linked cohort studies in England.

answer: @entity3


abstract: OBJECTIVE: Using a retrospective cohort study, the mean length of hospital stay (LoS) and total per- @entity0 expenditure for @entity3 requiring admission to hospital were estimated. In a separate matched retrospective cohort study, the effect of inpatient @entity3 on LoS, expenditure, and risk of all-cause mortality while admitted was investigated. METHODS: The cohorts consisted of @entity0 aged >= 18   years with a diagnosis of @entity2 1 or 2 @entity1 between January 1, 2002 and October 30, 2012 in the Clinical Practice Research Datalink database, who had initiated insulin treatment and had a recording of @entity3 in the same period. In the matched retrospective cohort study, exposed @entity0 (who experienced @entity3 in hospital) were case-matched with @entity0 who did not experience @entity3 during admission (unexposed). Generalized linear regression was used to estimate LoS. Risk of all-cause mortality was evaluated via logistic regression. RESULTS: In the retrospective cohort study (1131 @entity0 ), mean LoS was 5.46 (95% CI 4.62  to 6.45) days for @entity2 1 @entity1 , and 5.04 (95% CI 4.46 to 5.71) days for @entity2 2 @entity1 . Mean cost per admission was   1034 (95% CI   855 to   1253). In the matched retrospective cohort study (1079 pairs of @entity0 ), exposed @entity0 had a mean LoS of 11.91   days (95% CI 10.96  to 12.94   days) versus 4.80 (95% CI 4.41  to 5.23) for unexposed @entity0 , p<0.0001. Exposed @entity0 had a higher mortality risk compared with unexposed @entity0 (OR 1.439 (95% CI 1.060to 1.952), p=0.0195). Total average per- @entity0 cost for exposed @entity0 was GBP (  )2235, 40% (p<0.0001) higher than total average admission cost in unexposed @entity0 . CONCLUSIONS: @entity3 has a significant negative impact on @entity0 outcomes, healthcare resource use, and expenditure.

title: Healthcare resource implications of @entity3 -related hospital admissions and inpatient XXXX : retrospective record-linked cohort studies in England.

answer: @entity3


abstract: In conscious @entity0 peripheral cold stimuli decreased respiratory rate and increased cutaneous vasomotor tone while simultaneously renal sympathetic nervous discharge decreased. Peripheral warm stimuli produced the reverse pattern of autonomic effector activity. Injection of a bacterial endotoxin at warm ambient temperature elicited a biphasic @entity1 response. Within the first 60 min cutaneous vasomotor tone increased, simultaneously renal sympathetic activity decreased. Therefore, ear skin vessels dilated and renal sympathetic activity increased by about 100%. Respiratory rate remained @entity2 during both @entity1 phases. Renal blood flow was investigated in a second series of experiments and showed a negative stimulation but only in the first phase of @entity1 . The results show that renal innervation is involved in the typical thermoregulatory autonomic activity pattern by which temperature homeostasis is preserved. The vasomotor patterns of cold and heat stress developing during @entity1 are compatible with the concept of a changed set-point of the body thermostat. The @entity2 respiratory rate and the lack of the renal vascular response to the increased nervous activity during the second @entity1 phase and their reversal to normal after @entity3 ( @entity3 ) indicate the participation of prostaglandins modifying peripheral and central neurotransmitter mechanisms.

title: Renal and cutaneous vasomotor and respiratory rate adjustments to peripheral cold and warm stimuli and to bacterial endotoxin in conscious XXXX .

answer: @entity0


abstract: @entity5 ( @entity5 ) is a common inflammatory disease in elderly @entity0 . We present a case of a 49-year-old @entity0 diagnosed with @entity5 . The treatment with @entity2 resulted in a rapid resolution of clinical symptoms. However, inflammatory markers remained elevated. Ultrasonography and computed tomography revealed the presence of a large @entity1 . A cyst was suspected but, because of the high risk of @entity6 , a splenectomy was performed. The histopathological examination revealed the presence of @entity3 . Inflammatory markers returned to normal after splenectomy. @entity2 was tapered but clinical symptoms of @entity5 reappeared after lowering the dose of @entity2 <10 mg/day. Thus, treatment with @entity4 was started, which allowed for further tapering of @entity2 .

title: @entity5 in a @entity0 with XXXX - a case report.

answer: @entity3


abstract: @entity5 ( @entity5 ) is a common inflammatory disease in elderly @entity0 . We present a case of a 49-year-old @entity0 diagnosed with @entity5 . The treatment with @entity2 resulted in a rapid resolution of clinical symptoms. However, inflammatory markers remained elevated. Ultrasonography and computed tomography revealed the presence of a large @entity1 . A cyst was suspected but, because of the high risk of @entity6 , a splenectomy was performed. The histopathological examination revealed the presence of @entity3 . Inflammatory markers returned to normal after splenectomy. @entity2 was tapered but clinical symptoms of @entity5 reappeared after lowering the dose of @entity2 <10 mg/day. Thus, treatment with @entity4 was started, which allowed for further tapering of @entity2 .

title: XXXX in a @entity0 with @entity3 - a case report.

answer: @entity5


abstract: @entity5 ( @entity5 ) is a common inflammatory disease in elderly @entity0 . We present a case of a 49-year-old @entity0 diagnosed with @entity5 . The treatment with @entity2 resulted in a rapid resolution of clinical symptoms. However, inflammatory markers remained elevated. Ultrasonography and computed tomography revealed the presence of a large @entity1 . A cyst was suspected but, because of the high risk of @entity6 , a splenectomy was performed. The histopathological examination revealed the presence of @entity3 . Inflammatory markers returned to normal after splenectomy. @entity2 was tapered but clinical symptoms of @entity5 reappeared after lowering the dose of @entity2 <10 mg/day. Thus, treatment with @entity4 was started, which allowed for further tapering of @entity2 .

title: @entity5 in a XXXX with @entity3 - a case report.

answer: @entity0


abstract: BACKGROUND: Erythrasma is a superficial @entity2 caused by Corynebacterium minutissimum . @entity5 is the most common form and is easily confused with @entity4 . The aim of this study was to determine the prevalence of @entity5 in @entity0 with clinically suspected @entity4 . METHODS: This study was performed between January 1, 2011, and January 31, 2012. It included 182 @entity0 who presented with concerns about @entity1 . All of the @entity0 were examined with a Wood's lamp, and smears were stained with Gram's method. Direct examination with 20% @entity3 was performed. RESULTS: Of 182 @entity0 with @entity1 , 73 (40.1%) were diagnosed as having @entity5 . The mean    SD age of the @entity0 with @entity5 was 45.52    10.83 years (range, 22-70 years). Most of the @entity0 with @entity5 were @entity0 (56.2%). The most often clinical finding was desquamation. Using only Wood's lamp examination or Gram's staining resulted in 31 (42.5%) or 14 (19.2%) positive @entity0 , respectively. Using Wood's lamp examination and Gram's staining concurrently resulted in 28 positive @entity0 (38.4%). CONCLUSIONS: @entity5 is a common condition and can be difficult to differentiate from @entity4 . Simple and rapid diagnosis can be made with Wood's lamp examination, but Gram's staining is also a useful method, especially in @entity0 with negative Wood's lamp examination findings.

title: The prevalence of XXXX : a prospective study from an outpatient clinic in Turkey.

answer: @entity5


abstract: Management of @entity0 includes systematic therapies including chemotherapy and endocrine therapy can lead to a variety of symptoms that can impair the quality of life of many @entity0 survivors. @entity9 , caused by decreased levels of circulating @entity3 to urinary and vaginal receptors, is commonly experienced by this group. Chemotherapy induced @entity8 and endocrine therapies including aromatase inhibitors and selective @entity3 receptor modulators can trigger the onset of @entity9 or exacerbate existing symptoms. Symptoms of @entity9 include @entity6 , @entity5 , and irritation of genital skin, @entity2 , burning, vaginal discharge, and soreness. The diagnosis of @entity9 is confirmed through @entity1 -reported symptoms and gynecological examination of external structures, @entity10 . Lifestyle modifications can be helpful but are usually insufficient to significantly improve symptoms. Non-hormonal vaginal therapies may provide additional relief by increasing vaginal moisture and fluid. Systemic @entity3 therapy is contraindicated in @entity0 survivors. Continued investigations of various treatments for @entity9 are necessary. Local @entity3 -based therapies, @entity7 , @entity4 , and pH-balanced gels continue to be evaluated in ongoing studies. Definitive results are needed pertaining to the safety of topical @entity3 in @entity0 survivors.

title: @entity9 in XXXX survivors: a difficult survivorship issue.

answer: @entity0


abstract: Management of @entity0 includes systematic therapies including chemotherapy and endocrine therapy can lead to a variety of symptoms that can impair the quality of life of many @entity0 survivors. @entity9 , caused by decreased levels of circulating @entity3 to urinary and vaginal receptors, is commonly experienced by this group. Chemotherapy induced @entity8 and endocrine therapies including aromatase inhibitors and selective @entity3 receptor modulators can trigger the onset of @entity9 or exacerbate existing symptoms. Symptoms of @entity9 include @entity6 , @entity5 , and irritation of genital skin, @entity2 , burning, vaginal discharge, and soreness. The diagnosis of @entity9 is confirmed through @entity1 -reported symptoms and gynecological examination of external structures, @entity10 . Lifestyle modifications can be helpful but are usually insufficient to significantly improve symptoms. Non-hormonal vaginal therapies may provide additional relief by increasing vaginal moisture and fluid. Systemic @entity3 therapy is contraindicated in @entity0 survivors. Continued investigations of various treatments for @entity9 are necessary. Local @entity3 -based therapies, @entity7 , @entity4 , and pH-balanced gels continue to be evaluated in ongoing studies. Definitive results are needed pertaining to the safety of topical @entity3 in @entity0 survivors.

title: XXXX in @entity0 survivors: a difficult survivorship issue.

answer: @entity9


abstract: OBJECTIVE: To determine the prognostic CT and MR imaging features of extranodal @entity4 in the head and neck region. METHODS: The clinical data and CT and MR imaging features of 59 @entity0 with histologically confirmed extranodal @entity4 in the head and neck region were retrospectively reviewed. Subjects included 27 male and 32 female @entity0 between 13 and 81  years of age, with a mean age of 60.3  years. The clinical outcomes were categorized according to whether relapse or @entity1 occurred within 2  years after therapy. The association between the clinical outcome and radiologic factors including @entity2 size, margin, shape, @entity2 invasiveness, regional lymph node involvement, number of involvement sites, and contrast enhancement patterns was determined using univariate and multiple logistic regression analysis. RESULTS: Radiologic factors including @entity2 size, margin, shape, and @entity2 invasiveness were associated with poor clinical outcomes, as determined by univariate analysis (P   <   0.05). Only the lesion margin category (ill-defined) remained an independent risk factor for clinical outcome in multivariate logistic regression analysis, with an OR of 8.14 (P   <   0.05). CONCLUSION: Ill-defined margin of the @entity3 was indicative of unfavourable survival outcome for @entity0 with extranodal @entity4 of the head and neck region. KEY POINTS:     @entity2 size, margin, shape and @entity2 invasiveness were prognostically relevant.     @entity2 margin was an independent risk factor for clinical outcome.     Ill-defined margin of @entity3 was indicative of unfavourable survival outcome.

title: Prognostic CT and MR imaging features in @entity0 with untreated extranodal XXXX of the head and neck region.

answer: @entity4


abstract: OBJECTIVE: To determine the prognostic CT and MR imaging features of extranodal @entity4 in the head and neck region. METHODS: The clinical data and CT and MR imaging features of 59 @entity0 with histologically confirmed extranodal @entity4 in the head and neck region were retrospectively reviewed. Subjects included 27 male and 32 female @entity0 between 13 and 81  years of age, with a mean age of 60.3  years. The clinical outcomes were categorized according to whether relapse or @entity1 occurred within 2  years after therapy. The association between the clinical outcome and radiologic factors including @entity2 size, margin, shape, @entity2 invasiveness, regional lymph node involvement, number of involvement sites, and contrast enhancement patterns was determined using univariate and multiple logistic regression analysis. RESULTS: Radiologic factors including @entity2 size, margin, shape, and @entity2 invasiveness were associated with poor clinical outcomes, as determined by univariate analysis (P   <   0.05). Only the lesion margin category (ill-defined) remained an independent risk factor for clinical outcome in multivariate logistic regression analysis, with an OR of 8.14 (P   <   0.05). CONCLUSION: Ill-defined margin of the @entity3 was indicative of unfavourable survival outcome for @entity0 with extranodal @entity4 of the head and neck region. KEY POINTS:     @entity2 size, margin, shape and @entity2 invasiveness were prognostically relevant.     @entity2 margin was an independent risk factor for clinical outcome.     Ill-defined margin of @entity3 was indicative of unfavourable survival outcome.

title: Prognostic CT and MR imaging features in XXXX with untreated extranodal @entity4 of the head and neck region.

answer: @entity0


abstract: BACKGROUND: Ocular @entity2 is a common disease in daily practice. OBJECTIVES: A cross-sectional study was conducted to evaluate clinical aspects of and therapeutic approaches to @entity2 in Italy. METHODS: Of the 3685 @entity0 affected by @entity2 and enrolled by 304 ophthalmologists nationally, 3545 were eligible to be included in the statistical analysis. A questionnaire was administered in-office to record demographic data, co-morbidities, trigger factors, number of @entity4 episodes and past treatments. Signs and symptoms were graded according to their severity, frequency and duration. RESULTS: Mean age of enrolled @entity0 was 38  19 years. @entity1 (55% of @entity0 ) was equally distributed among the different age groups, while @entity1 (18%) increased with age and @entity5 (9%) was more frequent under the age of 18. Itching and redness were reported in 90% and 85%, respectively; lid skin involvement was observed in 22% of cases, and @entity3 in 11%. Pollen sensitivities were indicated as the most frequent triggers, however, exposure to non-specific environmental conditions, pollutants and cigarette smoke was frequently reported. Only 35% of @entity0 underwent a diagnostic evaluation of specific allergic sensitization, with positive @entity2 tests found in 82% of this subset. With regard to treatment, topical decongestants were used in 43% of @entity0 , corticosteroids in 41%, antihistamines in 29%, systemic antihistamines in 27%, and mast cell stabilizers in 15%. CONCLUSION: This survey provided useful epidemiological information regarding the clinical characteristics and treatment options of a large cohort of @entity0 affected by different forms of @entity2 . CLINICAL RELEVANCE: An understanding of @entity1 , its incidence, demographics and treatment paradigms, provides important information towards understanding its pharmacoeconomics and burden on the national health system. This article is protected by copyright. All rights reserved.

title: XXXX : a cross-sectional study.

answer: @entity1


abstract: BACKGROUND: Plant @entity7 (PSs) lower LDL @entity1 , an established risk factor for @entity4 ( @entity4 ). No direct evidence is available supporting a reduced risk of @entity4 for foods with added PSs. @entity3 is seen as an early indicator of @entity5 . OBJECTIVES: This study was primarily designed to investigate the effect of a low-fat spread with added PSs on brachial artery endothelial function as measured by @entity2 ( @entity2 ). Second, effects on arterial stiffness, blood pressure, serum lipids, and plasma PS concentrations were investigated. We hypothesized that PSs would not worsen @entity2 but would rather modestly improve @entity2 . DESIGN: This study had a double-blind, randomized, placebo-controlled, parallel design. After a 4-wk run-in period, 240 @entity6 but otherwise healthy @entity0 and @entity0 consumed 20 g/d of low-fat spread without (control) or with added PSs (3 g/d) during 12 wk. Pre- and postintervention, vascular function measurements and blood sampling were performed. RESULTS: In total, 232 @entity0 completed the study period. For the primary endpoint @entity2 , 199 @entity0 were included in the statistical analysis. PS intake did not affect @entity2 (+0.01 percentage points; 95% CI: -0.73, 0.75) compared with control. Measures of arterial stiffness (pulse wave velocity and augmentation index) and blood pressure were also not significantly changed compared with control. After PS intervention, LDL @entity1 significantly decreased on average by 0.26 mmol/L (95% CI: -0.40, -0.12) or 6.7% compared with control. Plasma @entity8 and @entity9 concentrations significantly increased in the PS group up to on average 11.5  mol/L and 13.9  mol/L (expressed as geometric means), respectively. CONCLUSIONS: The intake of a low-fat spread with added PSs neither improved nor worsened @entity2 or other vascular function markers in @entity6 @entity0 and @entity0 . As expected, serum LDL @entity1 decreased, whereas plasma PSs increased after PS intake. This study was registered at clinicaltrials.gov as NCT01803178.

title: The effect of a low-fat spread with added plant sterols on vascular function markers: results of the Investigating Vascular Function Effects of Plant XXXX (INVEST) study.

answer: @entity7


abstract: UNASSIGNED: While PCR is the most common method used for detecting @entity0 in the US, most laboratories use insertion sequence 481 (IS481), which is not specific for @entity0 ; therefore, the relative contribution of other @entity2 species is not understood. The objectives of this study were to evaluate the proportion of other @entity2 spp. misidentified as @entity0 during a period of increased pertussis incidence, determine the level of agreement in @entity2 species detection between US commercial laboratories and CDC, and assess the relative diagnostic sensitivity of CDC's PCR assay when using a different PCR master mix. Specimens collected between May 2012-2013 were tested at two US commercial laboratories for @entity0 and @entity2 detection. Every fifth specimen positive for IS481 and/or IS1001 with Ct values  <=35 was sent to CDC for PCR testing that identifies @entity2 species. Specimens with CDC PCR indeterminate or negative results were tested using an alternate PCR master mix. Of 755 specimens, there was agreement in species identification for 83.4% (n=630). Of those with different identifications (n=125), 79.2% (n=99) were identified as indeterminate @entity0 at CDC. Overall, 0.66% (n=5) of the specimens were identified as B. holmesii or @entity1 at CDC. Of 115 specimens with indeterminate or negative results, 46.1% (n=53) were @entity0 positive when tested by an alternate master mix, suggesting possible increase in assay sensitivity. This study demonstrates good agreement between the two US commercial laboratories and CDC and little misidentification of @entity2 species during the 2012 US epidemic.

title: An evaluation of the level of agreement in XXXX species identification in three United States laboratories during a period of increased pertussis.

answer: @entity2


abstract: OBJECTIVES: @entity7 ( @entity7 ) is a rare @entity2 entity, and the most common onset is in the @entity3 region ( @entity7 -HN). The data on diagnosis, treatment, and especially risk assessment concerning disease course and outcome are @entity4 . This study aimed to evaluate risk factors for local relapse (LR) and lymph node @entity1 (LNM) and their impact on progression-free survival (PFS). MATERIALS AND METHODS: In a retrospective monocentric study, @entity0 with @entity7 -HN treated between 1999 and 2011 were analyzed regarding clinical and histologic characteristics. Prognostic parameters for LR, LNM, and PFS were evaluated. In total, 89 @entity0 (55 male, 34 female, mean age of 71.8 years) with a mean follow-up time of 47.7 months (range 12-112) were included. RESULTS: LR occurred in four @entity0 (4.5%), LNM occurred in five @entity0 (5.6%). @entity0 with LNM had a significantly shorter PFS time (16.1 months) compared with @entity0 without LNM (154.2 months; P < .001). @entity2 depth and size (T classification), incomplete resection, localization at the ear, deep maximal vertical infiltration, muscle and vessel invasion all showed significant (P < .05) associations with LR, LNM, and shorter PFS time. @entity7 showed more histologic features of @entity6 ( @entity6 ), especially with regard to BerEP4 expression. CONCLUSION: While histology shows some typical characteristics of @entity6 , the biologic behavior and aggressiveness of @entity7 are similar to those of @entity5 . This is the first study to show that LR and, especially, LNM indicate a higher risk of an unfavorable outcome.

title: XXXX of the @entity3 : clinical and histologic characteristics and their impact on disease progression.

answer: @entity7


abstract: OBJECTIVES: @entity7 ( @entity7 ) is a rare @entity2 entity, and the most common onset is in the @entity3 region ( @entity7 -HN). The data on diagnosis, treatment, and especially risk assessment concerning disease course and outcome are @entity4 . This study aimed to evaluate risk factors for local relapse (LR) and lymph node @entity1 (LNM) and their impact on progression-free survival (PFS). MATERIALS AND METHODS: In a retrospective monocentric study, @entity0 with @entity7 -HN treated between 1999 and 2011 were analyzed regarding clinical and histologic characteristics. Prognostic parameters for LR, LNM, and PFS were evaluated. In total, 89 @entity0 (55 male, 34 female, mean age of 71.8 years) with a mean follow-up time of 47.7 months (range 12-112) were included. RESULTS: LR occurred in four @entity0 (4.5%), LNM occurred in five @entity0 (5.6%). @entity0 with LNM had a significantly shorter PFS time (16.1 months) compared with @entity0 without LNM (154.2 months; P < .001). @entity2 depth and size (T classification), incomplete resection, localization at the ear, deep maximal vertical infiltration, muscle and vessel invasion all showed significant (P < .05) associations with LR, LNM, and shorter PFS time. @entity7 showed more histologic features of @entity6 ( @entity6 ), especially with regard to BerEP4 expression. CONCLUSION: While histology shows some typical characteristics of @entity6 , the biologic behavior and aggressiveness of @entity7 are similar to those of @entity5 . This is the first study to show that LR and, especially, LNM indicate a higher risk of an unfavorable outcome.

title: @entity7 of the XXXX : clinical and histologic characteristics and their impact on disease progression.

answer: @entity3


abstract: Eight @entity0 with @entity5 (AVMs) underwent staged transcatheter @entity4 . Six @entity0 had AVMs involving an extremity, one had multiple pulmonary AVMs, and one had an AVM of the pancreas. Embolization was performed using Ivalon ( @entity6 ) particles and Gianturco coils. Clinical course, fever pattern, and appropriate enzymatic laboratory studies were monitored. @entity2 occurred in all but one @entity0 following embolization. A febrile course with the temperature reaching 39.6 degrees C without evidence of @entity1 was seen in several @entity0 for 3 to 5 days postembolization. Marked elevation in the @entity3 phosphokinase level and positive fibrin split products were noted in several instances. Because embolizations were performed in stages, serial arteriography was available. Embolization resulted in a reduction in symptoms in all eight @entity0 and allowed a more limited surgical procedure than would otherwise have been possible in two @entity0 . Complications occurred in three @entity0 and are described. It is concluded that transcatheter @entity4 is a useful therapeutic alternative in the management of congenital AVMs.

title: Embolization therapy in the management of XXXX .

answer: @entity5


abstract: OBJECTIVE: Activation of @entity13 ( @entity13 ) inhibits @entity4 but induces @entity7 . In vitro, it has been shown that @entity11 ( @entity11 ) inhibitor synergizes @entity13 ligand-induced macrophage @entity14 expression and @entity3 efflux. In this study, we determined whether @entity11 ( @entity9 ) and @entity13 ligand ( @entity12 ) can have a synergistic effect on the reduction of @entity4 while eliminating @entity13 ligand-induced @entity6 and @entity7 . We also set out to identify the cellular mechanisms of the actions. APPROACH AND RESULTS: Wild-type @entity0 were used to determine the effect of @entity9 on a high-fat diet or high-fat diet plus @entity12 -induced @entity8 and @entity2 . @entity10 deficient ( @entity10 (-/-)) @entity0 or @entity0 with advanced lesions were used to determine the effect of the combination of @entity12 and @entity9 on @entity4 and @entity7 . We found that @entity9 protected animals against @entity12 -induced transient or long-term hepatic lipid accumulation, @entity2 , and @entity7 . Meanwhile, the combination of @entity12 and @entity9 inhibited the development of @entity4 in a synergistic manner and @entity1 . Mechanistically, in addition to synergistic induction of macrophage @entity14 expression, the combination of @entity9 and @entity12 maintained arterial wall integrity, inhibited macrophage accumulation in aortas and formation of macrophages/foam cells, and activated reverse @entity3 transport. The inhibition of @entity12 -induced lipid accumulation by the combined @entity9 might be attributed to inactivation of lipogenesis and activation of lipolysis/ @entity5 oxidation pathways. CONCLUSIONS: Our study suggests that the combination of @entity11 inhibitor and @entity13 ligand can function as a novel therapy to synergistically reduce @entity4 while eliminating @entity13 -induced deleterious effects.

title: Inhibition of ERK1/2 and Activation of XXXX Synergistically Reduce Atherosclerotic Lesions in @entity10 -Deficient @entity0 .

answer: @entity13


abstract: OBJECTIVE: Activation of @entity13 ( @entity13 ) inhibits @entity4 but induces @entity7 . In vitro, it has been shown that @entity11 ( @entity11 ) inhibitor synergizes @entity13 ligand-induced macrophage @entity14 expression and @entity3 efflux. In this study, we determined whether @entity11 ( @entity9 ) and @entity13 ligand ( @entity12 ) can have a synergistic effect on the reduction of @entity4 while eliminating @entity13 ligand-induced @entity6 and @entity7 . We also set out to identify the cellular mechanisms of the actions. APPROACH AND RESULTS: Wild-type @entity0 were used to determine the effect of @entity9 on a high-fat diet or high-fat diet plus @entity12 -induced @entity8 and @entity2 . @entity10 deficient ( @entity10 (-/-)) @entity0 or @entity0 with advanced lesions were used to determine the effect of the combination of @entity12 and @entity9 on @entity4 and @entity7 . We found that @entity9 protected animals against @entity12 -induced transient or long-term hepatic lipid accumulation, @entity2 , and @entity7 . Meanwhile, the combination of @entity12 and @entity9 inhibited the development of @entity4 in a synergistic manner and @entity1 . Mechanistically, in addition to synergistic induction of macrophage @entity14 expression, the combination of @entity9 and @entity12 maintained arterial wall integrity, inhibited macrophage accumulation in aortas and formation of macrophages/foam cells, and activated reverse @entity3 transport. The inhibition of @entity12 -induced lipid accumulation by the combined @entity9 might be attributed to inactivation of lipogenesis and activation of lipolysis/ @entity5 oxidation pathways. CONCLUSIONS: Our study suggests that the combination of @entity11 inhibitor and @entity13 ligand can function as a novel therapy to synergistically reduce @entity4 while eliminating @entity13 -induced deleterious effects.

title: Inhibition of ERK1/2 and Activation of @entity13 Synergistically Reduce Atherosclerotic Lesions in XXXX -Deficient @entity0 .

answer: @entity10


abstract: OBJECTIVE: Activation of @entity13 ( @entity13 ) inhibits @entity4 but induces @entity7 . In vitro, it has been shown that @entity11 ( @entity11 ) inhibitor synergizes @entity13 ligand-induced macrophage @entity14 expression and @entity3 efflux. In this study, we determined whether @entity11 ( @entity9 ) and @entity13 ligand ( @entity12 ) can have a synergistic effect on the reduction of @entity4 while eliminating @entity13 ligand-induced @entity6 and @entity7 . We also set out to identify the cellular mechanisms of the actions. APPROACH AND RESULTS: Wild-type @entity0 were used to determine the effect of @entity9 on a high-fat diet or high-fat diet plus @entity12 -induced @entity8 and @entity2 . @entity10 deficient ( @entity10 (-/-)) @entity0 or @entity0 with advanced lesions were used to determine the effect of the combination of @entity12 and @entity9 on @entity4 and @entity7 . We found that @entity9 protected animals against @entity12 -induced transient or long-term hepatic lipid accumulation, @entity2 , and @entity7 . Meanwhile, the combination of @entity12 and @entity9 inhibited the development of @entity4 in a synergistic manner and @entity1 . Mechanistically, in addition to synergistic induction of macrophage @entity14 expression, the combination of @entity9 and @entity12 maintained arterial wall integrity, inhibited macrophage accumulation in aortas and formation of macrophages/foam cells, and activated reverse @entity3 transport. The inhibition of @entity12 -induced lipid accumulation by the combined @entity9 might be attributed to inactivation of lipogenesis and activation of lipolysis/ @entity5 oxidation pathways. CONCLUSIONS: Our study suggests that the combination of @entity11 inhibitor and @entity13 ligand can function as a novel therapy to synergistically reduce @entity4 while eliminating @entity13 -induced deleterious effects.

title: Inhibition of ERK1/2 and Activation of @entity13 Synergistically Reduce Atherosclerotic Lesions in @entity10 -Deficient XXXX .

answer: @entity0


abstract: OBJECTIVE: To ascertain the existence of discordance between perceived and measured balance in @entity0 with @entity1 and to examine the impact on walking speed and falls. DESIGN: A secondary analysis of a phase three, multicentered randomized controlled trial examining walking recovery following @entity1 . SUBJECTS: A total of 352 @entity0 from the Locomotor Experience Applied Post- @entity1 (LEAPS) trial. METHODS: @entity0 were categorized into four groups: two concordant and two discordant groups in relation to measured and perceived balance. Number and percentage of individuals with concordance and discordance were evaluated at two and 12 months. Walking speed and fall incidence between groups were examined. MAIN MEASURES: Perceived balance was measured by the Activities-Specific Balance Confidence scale, measured balance was determined by the Berg Balance Scale and gait speed was measured by the 10-meter walk test. RESULTS: Discordance was present for 35.8% of @entity0 at two months @entity1 with no statistically significant change in proportion at 12   months. Discordant @entity0 with high perceived balance and low measured balance walked 0.09   m/s faster at two months than @entity0 with concordant low perceived and measured balance (p   <   0.05). Discordant @entity0 with low perceived balance and high measured balance walked 0.15   m/s slower than those that were concordant with high perceived and measured balance (p         0.0001) at 12   months. Concordant @entity0 with high perceived and measured balance walked fastest and had fewer falls. CONCLUSIONS: Discordance existed between perceived and measured balance in one-third of individuals at two and 12   months post- @entity1 . Perceived balance impacted gait speed but not fall incidence.

title: Concordance and discordance between measured and perceived balance and the effect on gait speed and falls following XXXX .

answer: @entity1


abstract: UNASSIGNED: Chemotherapy is a mainstay of therapy for advanced @entity3 ( @entity3 ); however, owing to drug resistances, the effectiveness of chemotherapy is not satisfactory for some @entity0 with @entity3 . Therefore, identification of a marker that predicts treatment response is beneficial to @entity0 . Hypermethylation of transcription factor activating enhancer-binding protein 2    ( @entity4 ) has been implicated in chemotherapy resistance to fluorouracil-based chemotherapy in @entity0 with @entity2 , but its role in @entity3 is still unknown. In this study, we investigated @entity4 as a predictor of treatment response in @entity3 . We used methylation-sensitive high-resolution melting analysis to study the methylation of @entity4 in 141 @entity3 tissue specimens and 45 adjacent nontumor tissue specimens. In vitro experiments, we analyzed the expression and methylation of @entity4 and to examine the sensitivity of @entity3 cell lines to 5-fluorouracil (5-FU). The @entity4 methylation occurred at a significantly higher incidence rate in @entity1 tissues compared to adjacent nontumor tissues (chi-square [  (2)] = 38.919, P < .001). Hypermethylation of @entity4 occurred more frequently in @entity1 with lower differentiation grades (P < .001) and was significantly associated with nonresponse to fluorouracil-based chemotherapy (P = .010). Hypermethylation was also associated with decreased expression of @entity4 (P < .01) and nonresponse to 5-FU exposure in vitro (P < .001). Hypermethylation of @entity4 was associated with lack of response to fluorouracil-based chemotherapy, indicating that it might be a potential predictor of treatment response in @entity0 with @entity3 .

title: Transcription Factor AP2   : A Potential Predictor of Chemoresistance in @entity0 With XXXX .

answer: @entity3


abstract: UNASSIGNED: Chemotherapy is a mainstay of therapy for advanced @entity3 ( @entity3 ); however, owing to drug resistances, the effectiveness of chemotherapy is not satisfactory for some @entity0 with @entity3 . Therefore, identification of a marker that predicts treatment response is beneficial to @entity0 . Hypermethylation of transcription factor activating enhancer-binding protein 2    ( @entity4 ) has been implicated in chemotherapy resistance to fluorouracil-based chemotherapy in @entity0 with @entity2 , but its role in @entity3 is still unknown. In this study, we investigated @entity4 as a predictor of treatment response in @entity3 . We used methylation-sensitive high-resolution melting analysis to study the methylation of @entity4 in 141 @entity3 tissue specimens and 45 adjacent nontumor tissue specimens. In vitro experiments, we analyzed the expression and methylation of @entity4 and to examine the sensitivity of @entity3 cell lines to 5-fluorouracil (5-FU). The @entity4 methylation occurred at a significantly higher incidence rate in @entity1 tissues compared to adjacent nontumor tissues (chi-square [  (2)] = 38.919, P < .001). Hypermethylation of @entity4 occurred more frequently in @entity1 with lower differentiation grades (P < .001) and was significantly associated with nonresponse to fluorouracil-based chemotherapy (P = .010). Hypermethylation was also associated with decreased expression of @entity4 (P < .01) and nonresponse to 5-FU exposure in vitro (P < .001). Hypermethylation of @entity4 was associated with lack of response to fluorouracil-based chemotherapy, indicating that it might be a potential predictor of treatment response in @entity0 with @entity3 .

title: Transcription Factor AP2   : A Potential Predictor of Chemoresistance in XXXX With @entity3 .

answer: @entity0


abstract: Within the hippocampus, different kinds of spatial experience determine the direction of change of synaptic weights. Synaptic plasticity resulting from such experience may enable memory encoding. The @entity1 region is very striking in this regard: due to the distinct molecular properties of the @entity3 ( @entity3 ) and associational-commissural (AC) synapses, it is believed that they enable working memory and pattern completion. The question arises, however, as to how information reaching these synapses results in differentiated encoding. Given its crucial role in enabling persistent synaptic plasticity in other hippocampal subfields, we speculated that the metabotropic @entity2 receptor mGlu5 may regulate information encoding at @entity3 and AC synapses. Here, we show that antagonism of mGlu5 inhibits LTP, but not LTD at @entity3 synapses of freely behaving adult @entity0 . Conversely, mGlu5 antagonism prevents LTD but not LTP at AC- @entity1 synapses. This suggests that, under conditions in which mGlu5 is activated, LTP may be preferentially induced at @entity3 synapses, whereas LTD is favored at AC synapses. To assess this possibility, we applied 50 Hz stimulation that should generate postsynaptic activity that corresponds to   m, the activation threshold that lies between LTP and LTD. MGlu5 activation had no effect on AC responses but potentiated @entity3 synapses. These data suggest that mGlu5 serves as a switch that alters signal-to-noise ratios during information encoding in the @entity1 region. This mechanism supports highly tuned and differentiated information storage in @entity1 synapses.

title: mGlu5 Acts As a Switch for Opposing Forms of Synaptic Plasticity at Mossy Fiber- XXXX and Commissural Associational- @entity1 Synapses.

answer: @entity1


abstract: Within the hippocampus, different kinds of spatial experience determine the direction of change of synaptic weights. Synaptic plasticity resulting from such experience may enable memory encoding. The @entity1 region is very striking in this regard: due to the distinct molecular properties of the @entity3 ( @entity3 ) and associational-commissural (AC) synapses, it is believed that they enable working memory and pattern completion. The question arises, however, as to how information reaching these synapses results in differentiated encoding. Given its crucial role in enabling persistent synaptic plasticity in other hippocampal subfields, we speculated that the metabotropic @entity2 receptor mGlu5 may regulate information encoding at @entity3 and AC synapses. Here, we show that antagonism of mGlu5 inhibits LTP, but not LTD at @entity3 synapses of freely behaving adult @entity0 . Conversely, mGlu5 antagonism prevents LTD but not LTP at AC- @entity1 synapses. This suggests that, under conditions in which mGlu5 is activated, LTP may be preferentially induced at @entity3 synapses, whereas LTD is favored at AC synapses. To assess this possibility, we applied 50 Hz stimulation that should generate postsynaptic activity that corresponds to   m, the activation threshold that lies between LTP and LTD. MGlu5 activation had no effect on AC responses but potentiated @entity3 synapses. These data suggest that mGlu5 serves as a switch that alters signal-to-noise ratios during information encoding in the @entity1 region. This mechanism supports highly tuned and differentiated information storage in @entity1 synapses.

title: mGlu5 Acts As a Switch for Opposing Forms of Synaptic Plasticity at Mossy Fiber- @entity1 and Commissural Associational- XXXX Synapses.

answer: @entity1


abstract: CONTEXT: @entity0 with advanced @entity1 have a poor prognosis in spite of the best possible care. Primary debulking surgery has been the standard of care in advanced @entity1 ; however, it is associated with high mortality and morbidity rates as shown in various studies. Several studies have discussed the benefit of neoadjuvant chemotherapy in @entity0 with advanced @entity1 . AIMS: This study aims to evaluate the survival statistics of the @entity0 who have been managed with interval debulking surgery (IDS) from January 2007 to December 2009. MATERIALS AND METHODS: During the period from January 2007 to December 2009, a retrospective analysis of 104 @entity0 who underwent IDS for stage IIIC or IV @entity1 at our institute were selected for the study. IDS was attempted after three to five courses of chemotherapy with paclitaxal (175 mg/m(2) ) and @entity3 (5-6 of area under curve). @entity2 ( @entity2 ) and progression free survival (PFS) were compared with results of primary debulking study from existing literature. @entity2 and PFS rates were estimated by means of the Kaplan-Meier method. Results were statistically analyzed by IBM SPSS Statistics 19. RESULTS: The median @entity2 was 26 months and the median PFS was 18 months. In multivariate analysis it was found that both @entity2 and PFS was affected by the stage, and extent of debulking. CONCLUSIONS: Neoadjuvant chemotherapy, followed by surgical cytoreduction is a promising treatment strategy for the management of @entity1 .

title: Neoadjuvant chemotherapy in XXXX : A survival study.

answer: @entity1